Clinical trial · Observational
Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant
Association Between Pre-operative Use of Non-selective Beta-blockers With the Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation : a Retrospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to investigate the effect of non-selective beta-blocker (NSBB) on the recurrence of hepatocellular carcinoma (HCC) following liver transplantation in patients who underwent liver transplantation (LT) for treating hepatocellular carcinoma. The main question\[s\] it aims to answer are: * Is the usage of non-selective beta-blocker associated with decreased recurrence of hepatocellular carcinoma following liver transplantation? * Is the usage of non-selective beta-blocker associated with all-cause mortality following liver transplantation? Researchers will compare the NSBB group, including patients who received non-selective beta-blocker therapy for at least 30 consecutive days within 3 months prior to liver transplantation more than 30 days prior, with the control group to to see if non-selective beta-blocker treatment is associated with decreased recurrence of hepatocellular carcinoma following liver transplantation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Hepatocellular Carcinoma Recurrent | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- NSBB group
- description
- The NSBB group was defined as those who received NSBBs for at least 30 consecutive days within the 3 months prior to LT.
- interventionNames
- Drug: Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use
- label
- Control group
- description
- Those who did not meet the above criteria were classified as the control group.
Primary outcomes (2)
- measure
- Kaplan-Meier survival analysis of HCC recurrence at 5-year follow-up
- timeFrame
- Baseline and 5-year follow-up
- description
- HCC recurrence, which was diagnosed based on pathological or radiographic evidence of new lesions consistent with HCC, and recurrence-free survival was collected and compared using Kaplan-Meier survival analysis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients * Underwent liver transplantation for treating hepatocellular carcinoma * Between Jan. 2008 - May. 2022 Exclusion Criteria: * Pediatric patients (Age under 18 years) * Re-transplantation * Multi-organ transplantation
References
Publications (0)
Data not yet available